Multiple Myeloma Clinical Trial
This protocol is a randomized, open-label, national, multicenter trial studying maintenance
treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and MLN9708
after autologous hematopoietic stem cell transplantation in patients with newly-diagnosed
symptomatic multiple myeloma.
A total of 316 patients, from the study GEM2012MENOS65, will be enrolled in the study.
The pre-treatment period includes the screening visit in which participants provide informed
consent in writing in order to take part in the study. The patient is then assessed to
determine his/her eligibility. The selection process will begin 21 days before the first dose
of medication is administered (days -21 to 0). All procedures during the pre-treatment period
will be carried out after completion of the two cycles of post-transplant consolidation with
VRD which coincide with the end-of-study visit of clinical trial GEM2012MENOS65.
During the treatment period, eligible patients will be included in the study and receive
maintenance treatment with lenalidomide/dexamethasone versus
lenalidomide/dexamethasone/MLN9708. Each cycle will last 28 days. Treatment arm A will
consist of oral administration of 15 mg/day of oral lenalidomide on days 1-21, and 20 mg/day
of dexamethasone administered orally on days 1-4 and 9-12 for a period of two years. Arm B of
the maintenance treatment will be the same as arm A, with the addition of MLN9708 during the
two year maintenance period, at a dose of 4 mg/day on days 1, 8 and 15 of the cycle.
At two years, patients with negative MRD will finish maintenance treatment. Patients with
positive MRD will continue treatment with lenalidomide/dexamethasone until they have
completed five years of maintenance treatment. In this case, 20 mg/day of dexamethasone will
only be administered on days 1-4 of the cycle. The dose of lenalidomide will not be adjusted.
(unless necessary to treat adverse events)
Once this phase of active treatment is complete, patients will begin the long-term follow-up
phase, during which they will be visited every three months to evaluate progression and
survival.
The primary trial objectives are:
• Impact on progression-free survival (PFS) when adding MLN9708 to post-transplant
maintenance treatment with lenalidomide/dexamethasone in patients with multiple myeloma.
The secondary trial objectives are:
- Evaluate development and clinical significance of minimal residual disease (MRD) from
the time maintenance treatment is initiated, yearly over five years.
- Overall survival (OS).
- Evaluate the safety and tolerability of the maintenance treatment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
| Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
| Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
| Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |